Our top pick for
Building a portfolio
Zogenix, Inc is a biotechnology business based in the US. Zogenix shares (ZGNX) are listed on the NASDAQ and all prices are listed in US Dollars. Zogenix employs 218 staff and has a trailing 12-month revenue of around USD$13.6 million.
|52-week range||USD$17.2033 - USD$32.42|
|50-day moving average||USD$20.5509|
|200-day moving average||USD$20.3837|
|Wall St. target price||USD$48.7|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.32|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$13.6 million|
|Gross profit TTM||USD$-124,901,000|
|Return on assets TTM||-26.8%|
|Return on equity TTM||-68.12%|
|Market capitalisation||USD$1.1 billion|
TTM: trailing 12 months
There are currently 8.8 million Zogenix shares held short by investors – that's known as Zogenix's "short interest". This figure is 1.3% down from 8.9 million last month.
There are a few different ways that this level of interest in shorting Zogenix shares can be evaluated.
Zogenix's "short interest ratio" (SIR) is the quantity of Zogenix shares currently shorted divided by the average quantity of Zogenix shares traded daily (recently around 709409.59677419). Zogenix's SIR currently stands at 12.4. In other words for every 100,000 Zogenix shares traded daily on the market, roughly 12400 shares are currently held short.
However Zogenix's short interest can also be evaluated against the total number of Zogenix shares, or, against the total number of tradable Zogenix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zogenix's short interest could be expressed as 0.16% of the outstanding shares (for every 100,000 Zogenix shares in existence, roughly 160 shares are currently held short) or 0.1586% of the tradable shares (for every 100,000 tradable Zogenix shares, roughly 159 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Zogenix.
Find out more about how you can short Zogenix stock.
We're not expecting Zogenix to pay a dividend over the next 12 months.
Zogenix's shares were split on a 1:8 basis on 30 June 2015. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Zogenix shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Zogenix shares which in turn could have impacted Zogenix's share price.
Over the last 12 months, Zogenix's shares have ranged in value from as little as $17.2033 up to $32.42. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Zogenix's is 1.4606. This would suggest that Zogenix's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.